Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Thalidomide × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡